Saturday 17 October 2026 Export COLL’s income statement to Excel — free account

Collegium Pharmaceutical, Inc.

COLL Healthcare Drug Manufacturers Specialty & Generic

Collegium Pharmaceutical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $780.6 million, up 23.6% from fiscal 2024. In the quarter to June 2026, revenue grew 6.32%, EPS fell 221.1%, free cash flow fell 2.14% and total debt rose 32.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

23.19 0.01 +0.04%

Follow COLL

Alert me

Market cap: $754.6M
P/E: 15.2×
Fwd P/E: 12.5×
Dividend yield: —
F-score: 7/9
Altman Z: 1.58
Beneish M: −3.32
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 7.25

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	2	2	—	—	3	—	4	—	—	—	—	—

Insider Ownership 1.57%

Capital & Financial Ratios $m

Market Cap 754.64

Revenue 808.21

Net Income 47.92

Free Cash Flow 328.28

Net Debt 942.24

Current Ratio 1.03

Debt/Equity 3.50

P/E ratio 15.16

Fwd P/E 12.50

P/S ratio 0.93

P/B ratio 2.41

Past 5Y EPS Growth 17.88%

This Y EPS Growth 0.52%

Next Y EPS Growth (2.68%)

Next Y revenue growth 6.85%

Next 5Y EPS Growth 1.25%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 46.01%

10-year low 10-year high

P/S against its own 10 years 1.16%

10-year low 10-year high

P/B against its own 10 years 2.69%

10-year low 10-year high

EV/Sales against its own 10 years 18.49%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	311	188	407	149
Receivables	180	229	211	285
Inventory	32	36	41	113
Other	—	—	—	—
	538	482	691	608

	2023	2024	2025	Q'26
Payables	9	4	11	9
ST’ Debt	183	65	29	55
Other	—	29	18	45
	458	510	440	590

Compound Annual Growth %

	10y	5y	3y
Sales	—	20.28%	18.94%
Cash Flow	0.00%	28.51%	38.40%
Earnings	0.00%	18.64%	0.00%
Book Value	13.49%	10.15%	15.69%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	194	200	—	—	—
’25	178	188	209	205	781
’24	145	145	159	182	631
’23	145	136	137	150	567
’22	84	124	127	130	464
’21	88	83	79	27	277
’20	77	78	79	76	310

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	57	71	—	—	—
’25	55	72	78	123	329
’24	62	67	(9)	85	205
’23	28	100	74	73	275
’22	(25)	40	43	66	124
’21	21	30	17	36	104
’20	(7)	44	34	23	94

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	57	71	—	—	—
’25	55	72	78	122	328
’24	61	67	(9)	84	203
’23	27	100	74	73	274
’22	(25)	40	43	65	123
’21	20	29	17	36	102
’20	(374)	42	32	21	(280)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.40	(0.46)	—	—	—
’25	0.07	0.34	0.84	0.46	1.73
’24	0.71	0.52	0.27	0.36	1.86
’23	(0.51)	0.34	0.53	0.82	1.29
’22	(0.39)	(0.15)	0.01	(0.21)	(0.74)
’21	0.41	1.79	0.22	(0.73)	1.86
’20	0.01	0.23	0.32	0.20	0.76

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	8.24	7.37	13.70	10.01	13.00	17.22	14.04	20.83	28.47	23.23	Analyst estimates 2026–2028 Powerpack
	High	28.47	20.92	29.90	22.28	25.59	26.91	24.36	31.12	42.29	50.79
People
People	Employees	234	250	266	255	234	152	207	197	357	423
	Revenue/emp, $m	0.01	0.11	1.05	1.16	1.32	1.82	2.24	2.88	1.77	1.85
Income, $m
Income, $m	Revenue	2	28	280	297	310	277	464	567	631	781
	Gross margin, %	87.55	90.89	40.92	34.73	58.01	54.40	45.15	57.55	59.76	59.35
	EBT	(94)	(75)	(39)	(23)	28	(3)	(29)	76	99	93
	EBT margin, %	(5,504.15)	(262.91)	(13.95)	(7.66)	8.90	(1.22)	(6.22)	13.36	15.61	11.87
	Net income	(94)	(75)	(39)	(23)	27	72	(25)	48	69	63
	Depreciation	1	1	111	15	62	69	139	148	167	225
Per share, $
Per share, $	Revenue	0.07	0.94	8.51	8.87	9.01	7.92	13.71	16.80	19.57	24.62
	Earnings	(3.88)	(2.47)	(1.19)	(0.68)	0.78	2.05	(0.74)	1.43	2.14	1.98
	Cash flow	(3.09)	(2.21)	5.14	0.83	2.73	2.96	3.67	8.14	6.35	10.39
	Capex	(0.02)	(0.03)	(0.74)	(0.19)	(10.86)	(0.06)	(0.05)	(0.01)	(0.05)	(0.05)
	Free cash flow	(3.11)	(2.25)	4.40	0.64	(8.13)	2.91	3.62	8.13	6.30	10.33
	Book value	5.56	3.44	2.78	2.61	5.41	5.81	5.76	5.79	7.09	9.51
	Shares, m	24	30	33	33	34	35	34	34	32	32
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	26.01	9.29	0.00	21.24	13.39	23.15
	P/S	0.00	19.87	2.02	2.32	2.22	2.36	1.72	1.86	1.46	1.88
	P/B	2.82	5.44	6.18	7.87	3.70	3.22	4.09	5.39	4.04	4.87
	EV/Sales	0.00	15.77	1.54	1.79	2.49	2.59	2.86	2.49	2.52	2.40
	EV/FCF	(3.06)	(6.60)	3.02	(16,561.38)	(2.76)	(2.69)	(5.39)	(15.01)	(9.64)	(46.03)
Cash, $m
Cash, $m	Operating cash flow	(75)	(67)	169	28	94	104	124	275	205	329
	Capex	0	(1)	(24)	(6)	(374)	(2)	(2)	0	(2)	(2)
	Free cash flow	(76)	(68)	145	21	(280)	102	123	274	203	328
Balance, $m
Balance, $m	Working capital	133	102	48	54	38	36	(14)	80	(27)	251
	Total debt	4	1	12	12	257	250	701	667	852	809
	Net debt	(149)	(117)	(135)	(159)	83	64	527	357	665	403
	Shareholders’ equity	135	104	92	87	186	203	195	195	229	302
Returns, %
Returns, %	ROA	(72.52)	(50.32)	(18.33)	(7.61)	5.63	10.71	(2.68)	4.16	4.93	3.79
	ROIC	0.00	0.00	0.00	0.00	13.06	4.13	2.88	18.90	11.88	15.94
	ROE	(85.62)	(62.65)	(39.99)	(25.39)	19.57	36.77	(12.57)	24.68	32.62	23.70

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CRON Cronos Group Inc.	$1.2B	16.1×	32.2×	+58.44% (above 0%: growing)	n/m	+2,279.22% (above 0%: growing)	53.67%	13.97%	Compare
AMPH Amphastar Pharmaceuticals, Inc.	$1.1B	14.9×	14.7×	+5.44% (above 0%: growing)	+4.55% (above 0%: growing)	+87.61% (above 0%: growing)	50.83%	21.60%	Compare
HROW Harrow, Inc.	$1.1B	— (loss-making)	134×	+10.85% (above 0%: growing)	n/m	−838.78% (below 0%: shrinking)	71.27%	(15.58%)	Compare
COLL Collegium Pharmaceutical, Inc.	$754.6M	15.2×	12.5×	+6.32% (above 0%: growing)	n/m	−2.14% (below 0%: shrinking)	55.18%	1.85%
IRWD Ironwood Pharmaceuticals, Inc.	$623.0M	4.4×	2.8×	+32.62% (above 0%: growing)	+106.67% (above 0%: growing)	+486.70% (above 0%: growing)	100.00%	70.16%	Compare
AQST Aquestive Therapeutics, Inc.	$509.6M	— (loss-making)	— (loss-making)	+38.15% (above 0%: growing)	n/m	−20.35% (below 0%: shrinking)	70.93%	(59.51%)	Compare
EVO Evotec AG	$504.4M	— (loss-making)	— (loss-making)	−12.98% (below 0%: shrinking)	n/m	−9,727.20% (below 0%: shrinking)	(1.00%)	(77.50%)	Compare
EOLS Evolus, Inc.	$500.0M	— (loss-making)	— (loss-making)	+21.18% (above 0%: growing)	n/m	+84.90% (above 0%: growing)	68.00%	(5.40%)	Compare
TLRY Tilray Brands, Inc.	$474.4M	— (loss-making)	— (loss-making)	+22.74% (above 0%: growing)	n/m	−36.60% (below 0%: shrinking)	30.14%	(9.35%)	Compare
Median of peers	$566.3M	14.9×	23.5×	+21.96%	—	+32.28%	60.84%	(7.37%)

All 86 Drug Manufacturers Specialty & Generic stocks →

Collegium Pharmaceutical, Inc. (COLL) key facts

Strength: Collegium Pharmaceutical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $780.6 million, up 23.6% from fiscal 2024.
Collegium Pharmaceutical, Inc. (COLL) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, COLL traded at $23.19, a market capitalization of $754.6 million.
Return on equity was 23.7% and debt-to-equity 3.50.
Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 1.58 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.